Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2045

Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.

Patents
1,566

Quick answer

1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12202822

    Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition

    SuZhou Connect Biopharmaceuticals, Inc. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12203106

    Compositions for increasing polypeptide stability and activity, and related methods

    Solis BioDyne OÜ · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12203072

    Chemically modified single-stranded rna-editing oligonucleotides

    ProQR Therapeutics II B.V. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12203143

    Methods and kits to identify Klebsiella strains

    Arizona Board of Regents on Behalf of Northern Arizona University · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12201593

    Oral pharmaceutical formulations of bitter compounds for asthma

    Aardvark Therapeutics, Inc. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12202832

    Heterocyclic compounds having a calcium-sensing receptor antagonistic activity

    Takeda Pharmaceutical Company Limited · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12201700

    Micro- and nano-device for cartilage injury detection and treatment

    The Board of Regents of the University of Texas System · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12202895

    LILRB4 antibodies and uses thereof

    The Board of Regents of the University of Texas System · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12201639

    Aqueous oral pharmaceutical suspension compositions

    ReveraGen BioPharma, Inc. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12201596

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12201453

    Microneedle fabrication and device implantation

    The Regents of the University of California · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12202880

    HLA engineering methods and compositions for treatment of autoimmunity

    The Regents of the University of Colorado · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12202877

    T cell receptors with mage-B2 specificity and uses thereof

    The Board of Regents of the University of Texas System · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12201699

    Compositions and methods for promoting homology directed repair

    Editas Medicine, Inc. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12201617

    HDAC6 inhibitors for treatment of metabolic disease and HFpEF

    Tenaya Therapeutics, Inc. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12201591

    Sustained release compositions of endoxifen

    ATOSSA THERAPEUTICS, INC. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12202901

    Cannabinoid receptor type 1 (CB1) antibodies, encoding nucleic acid molecules thereof and methods of use thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12202886

    Neutralizing antibodies to GP120 and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12203098

    Cells having solid tumor targeting backbone and use thereof

    Fate Therapeutics, Inc. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12201673

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12201719

    Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

    VACCINEX, INC. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12201604

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12202883

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12201655

    Antimicrobial therapy

    The Regents of the University of California · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12202841

    Therapeutic agents for enhancing epithelial and/or endothelial barrier function

    INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. WO 2025018295

    BACTÉRIOPHAGE MODIFIÉ

    ASTELLAS PHARMA INC [JP] · Granted Thu Jan 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. CN 119365549

    Fluorescent probe targeting CA-IX

    BRACCO IMAGING SPA · Granted Fri Jan 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Thu Jan 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12210017

    Peptides representing epitopes from filoviruses

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12208099

    Combination therapies

    Mirati Therapeutics, Inc. · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12208167

    Coated tablets for pH-dependent release of benzgalantamine

    ALPHA COGNITION INC. · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12209119

    Method of treating rheumatoid arthritis using antibodies to oxidized phospholipids

    The Regents of the University of California · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12209255

    Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof

    Astellas Institute for Regenerative Medicine · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12209138

    Anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12209238

    CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12208148

    Dental restorative curable composition

    KURARAY NORITAKE DENTAL INC. · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12209073

    Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor

    KIORA PHARMACEUTICALS GmbH · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12209116

    Recombinant human C1 esterase inhibitor and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12209256

    System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12208092

    Compositions and methods for administering paltusotine to patients with hepatic impairment

    CRINETICS PHARMACEUTICALS, INC. · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12209140

    Therapeutics for the treatment of glaucoma

    Regents of the University of Minnesota · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12209135

    Anti-CD45 antibodies and conjugates thereof

    Vor Biopharma Inc. · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12208123

    Compositions and methods for the treatment of skin conditions

    DERMATA THERAPEUTICS, INC. · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12209240

    Antisense antibacterial compounds and methods

    The Board of Regents of the University of Texas System · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12208071

    Glucagon receptor antagonists

    Ligand Pharmaceuticals Incorporated · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12209142

    SARS-CoV-2 epitope-targeted peptide immunostimulants

    The United States of America as represented by the Secretary of the Army · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12208069

    Antibiofilm formulations

    Arizona Board of Regents on Behalf of Northern Arizona University · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12209120

    Activatable anti-VEGF scFv

    The Regents of the University of California · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12209180

    Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2045?

1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.